Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 107,470 shares, a decrease of 78.8% from the July 15th total of 506,729 shares. Approximately 3.6% of the company’s shares are sold short. Based on an average daily trading volume, of 138,757 shares, the short-interest ratio is presently 0.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Exicure has a consensus rating of “Sell”.

Exicure Stock Down 3.8%

Exicure stock traded down $0.05 during trading hours on Friday, hitting $1.26. The stock had a trading volume of 11,393 shares, compared to its average volume of 178,929. The stock has a market capitalization of $8.03 million, a P/E ratio of -0.81 and a beta of 3.65. Exicure has a 12-month low of $1.18 and a 12-month high of $9.48. The stock’s 50-day moving average price is $1.99 and its 200-day moving average price is $3.16.

Exicure (NASDAQ:XCUR) last released its quarterly earnings data on Friday, May 29th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.31.

About Exicure

Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.